Mineralocorticoid Receptor Antagonists in Cardiovascular Medicine: Looking for the Forest Among the Trees

Author(s): Konstantinos V. Stavropoulos, Konstantinos P. Imprialos, Michael Doumas, Charles J. Faselis.

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 46 , 2018


[1]
Cranston WI, Juel-Jensen BE. The effects of spironolactone and chlorthalidone on arterial pressure. Lancet 1962; 1: 1161-4.
[2]
Faselis C, Boutari C, Doumas M, et al. Novel drugs for hypertension and heart failure: struggling for a place under the sun. Curr Pharm Des 2017; 23: 1540-50.
[3]
Sarafidis PA, Georgianos PI, Bakris GL. Advances in treatment of hyperkalemia in chronic kidney disease. Expert Opin Pharmacother 2015; 16: 2205-15.
[4]
Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011; 32: 820-8.
[5]
Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015; 372: 211-21.
[6]
Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015; 372: 222-31.
[7]
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71: e13-e115.
[8]
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018; 36: 1953-2041.
[9]
Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386: 2059-68.
[10]
Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101: 1889-916.
[11]
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
[12]
Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
[13]
Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
[14]
Bayoumi E, Lam PH, Dooley DJ, et al. Spironolactone and outcomes in older patients with heart failure and reduced ejection fraction. Am J Med 2018.
[http://dx.doi.org/10.1016/j.amjmed.2018.09.011 [Epub ahead of print].]
[15]
Mottram PM, Haluska B, Leano R, et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004; 110: 558-65.
[16]
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975.
[17]
Bomback AS, Muskala P, Bald E, et al. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduced blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage. Clin Nephrol 2009; 72: 449-56.
[18]
Mehdi UF. ms-Huet B, Raskin P, et al Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2641-50.
[19]
Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol 2012; 350: 310-7.
[20]
Kolkhof P, Nowack C, Eitner F. Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens 2015; 24: 417-24.
[21]
Ruilope LM, Tamargo J. Renin-angiotensin system blockade: Finerenone. Nephrol Ther 2017; 13: S47-53.
[22]
Mulder P. BarreraChimal J, El Moghrabi S, et al Finerenone improves diastolic function in a preclinical model of type 2 diabetes mellitus. Eur Heart J 2016; 37: 829.
[23]
Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, et al. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone-results from first-in-man and relative bioavailability studies. Fundam Clin Pharmacol 2016; 30: 172-84.
[24]
Heining R, Kimmeskamp-Kirschbaum N, Halabi A, et al. Pharmacokinetics of the novel Non-steroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment. Clin Pharmacol Drug Dev 2016; 5: 488-501.
[25]
Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial. Eur Heart J 2013; 34: 2453-6.
[26]
Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 2016; 37: 2105-14.
[27]
Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 2015; 314: 884-9.
[28]
Pantelidis P, Sideris M, Avranas K, et al. The mechanism of actions of aldosterone and its antagonists in cardiovascular disease. Curr Pharm Des 2018; 24(46): 5491-9.
[29]
Imprialos KP, Bouloukou S, Kerpiniotis G, et al. Mineralocorticoid receptor antagonists in essential and resistant hypertension. Curr Pharm Des 2018; 24(46): 5500-7.
[30]
Stavropoulos K, Papadopoulos C, Koutsampasopoulos K, et al. Mineralocorticoid receptor antagonists in primary aldosteronism. Curr Pharm Des 2018; 24(46): 5508-16.
[31]
Papademetriou V, Toumpourleka M, Imprialos KP, et al. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction. Curr Pharm Des 2018; 24(46): 5517-24.
[32]
Papagiannis A, Alkagiet S, Tziomalos K. The role of mineralocorticoid receptor antagonists in the managemnet of heart failure with perserved ejection fraction. Curr Pharm Des 2018; 24(46): 5525-7.
[33]
Sarafidis PA, Memmos E, Alexandrou M-E, Papagianni A. Mineralocorticoid receptor antagonists for nephroprotection: Current evidence and future perspectives. Curr Pharm Des 2018; 24(46): 5528-36.
[34]
Kallistratos MS, Pittaras A, Theodoulidis I, et al. Adverse effects of mineralocorticoid receptor antagonist administration. Curr Pharm Des 2018; 24(46): 5537-41.
[35]
Athyros VG, Sachinidis AG, Zografou I, et al. Boosting the limited use of mineralocorticoid receptor antagonists through new agents for hyperkalemia. Curr Pharm Des 2018; 24(46): 5542-7.
[36]
Dimitriadis K, Tsioufis C, Iliakis P, et al. Future anti-aldosterone agents. Curr Pharm Des 2018; 24(46): 5548-54.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 24
ISSUE: 46
Year: 2018
Page: [5489 - 5490]
Pages: 2
DOI: 10.2174/138161282446190426120024

Article Metrics

PDF: 33
HTML: 4
EPUB: 1
PRC: 1

Special-new-year-discount